COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges

References

• WHO. WHO COVID-19 dashboard - up to date data on pandemic. WHO Heal Emerg Dasboard 2021. https://covid19.who.int/region/searo/country/id [Accessed on February 8, 2022]
   Google Scholar
• Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 2020;33(4):1–11. doi:10.1128/CMR.00028-20.
   Web of Science ®Google Scholar
• Sharun K, Tiwari R, Iqbal Yatoo M, Patel SK, Natesan S, Dhama J, Malik YS, Harapan H, Singh RK, Dhama K. Antibody-Based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. Expert Opin Biol Ther. 2020;20(9):1033–46. doi:10.1080/14712598.2020.1796963.
   PubMed Web of Science ®Google Scholar
• Ghareeb DA, Saleh SR, Nofal MS, Kaddah MMY, Hassan SF, Seif IK, El-Zahaby SA, Khedr SM, Kenawy MY, Masoud AA. Potential therapeutic and pharmacological strategies for SARS-CoV2. J Pharm Investig. 2021;51(3):281–96. doi:10.1007/s40005-021-00520-4.
   PubMed Web of Science ®Google Scholar
• Hyder Pottoo F, Abu-Izneid T, Mohammad Ibrahim A, Noushad Javed M, AlHajri N, Hamrouni AM. Immune system response during viral infections: immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. Saudi Pharm J. 2021;29(2):173–87. doi:10.1016/j.jsps.2020.12.018.
   PubMed Web of Science ®Google Scholar
• Ita K. Coronavirus disease (COVID-19): current status and prospects for drug and vaccine development. Arch Med Res. 2021;52(1):15–24. doi:10.1016/j.arcmed.2020.09.010.
   PubMed Web of Science ®Google Scholar
• Iqbal Yatoo M, Hamid Z, Rather I, Nazir QUA, Bhat RA, Ul Haq A, Magray SN, Haq Z, Sah R, Tiwari R, et al. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. Hum Vaccines Immunother. 2021;17(7):1897–909. doi:10.1080/21645515.2020.1871295.
   PubMed Web of Science ®Google Scholar
• Iqbal Yatoo M, Hamid Z, Parray OR, Wani AH, Ul Haq A, Saxena A, Patel SK, Pathak M, Tiwari R, Malik YS, et al. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Hum Vaccines Immunother. 2020;16(12):2891–904. doi:10.1080/21645515.2020.1788310.
   PubMed Web of Science ®Google Scholar
• Ashraf MU, Kim Y, Kumar S, Seo D, Ashraf M, Bae YS. Covid-19 vaccines (Revisited) and oral-mucosal vector system as a potential vaccine platform. Vaccines. 2021;9(2):1–24. doi:10.3390/vaccines9020171.
   Web of Science ®Google Scholar
• García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, Guijarro LG, García-Honduvilla N, Asúnsoloúnsolo A, Bujan J, et al. An updated review of sars-cov-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5):433. doi:10.3390/vaccines9050433.
   PubMed Web of Science ®Google Scholar
• Rawat K, Kumari P, and Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892:173751. doi:10.1016/j.ejphar.2020.173751.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Covid-19. Draft landscape of COVID-19 candidate vaccines. Who; 2020. 3. Available from.
   PubMed Web of Science ®Google Scholar
• Dhama K, Natesan S, Iqbal Yatoo M, Patel SK, Tiwari R, Saxena SK, Harapan H. Plant-Based vaccines and antibodies to combat COVID-19: current status and prospects. Hum Vaccines Immunother. 2020;16(12):2913–20. doi:10.1080/21645515.2020.1842034.
   PubMed Web of Science ®Google Scholar
• Malik YS, Sircar S, Bhat S, Ansari MI, Pande T, Kumar P, Mathapati B, Balasubramanian G, Kaushik R, Natesan S, et al. How artificial intelligence may help the Covid-19 pandemic: pitfalls and lessons for the future. Rev Med Virol. 2020;31(5):1–11. doi:10.1002/rmv.2205.
   PubMed Web of Science ®Google Scholar
• Monrad JT, Sandbrink JB, Cherian NG. Promoting versatile vaccine development for emerging pandemics. NPJ Vaccines. 2021;6(1):6. doi:10.1038/s41541-021-00290-y.
   PubMed Web of Science ®Google Scholar
• Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, Ahmadian G. Virus-Like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology. 2021;19(1). doi:10.1186/s12951-021-00806-7.
   Web of Science ®Google Scholar
• Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021;39:197–201. doi:10.1016/j.vaccine.2020.11.054.
   PubMed Web of Science ®Google Scholar
• Rao VB, Zhu J, Ananthaswamy N, Jain S, Batra H, Tang W-C, Lewry DA, Richards ML, David SA, Kilgore PB, et al. A universal Bacteriophage T4 nanoparticle platform to design Multiplex SARS-CoV-2 vaccine candidates by CRISPR Engineering. bioRxiv. 2021;2021.01.19.427310.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384:1576–78.
   PubMedGoogle Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford–astrazeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74. doi:10.1016/S0140-6736(20)32623-4.
   PubMed Web of Science ®Google Scholar
• Rasmussen AL. Vaccination is the only acceptable path to herd immunity. Med. 2020;1:21–23. doi:10.1016/j.medj.2020.12.004.
   PubMedGoogle Scholar
• Vora KS, Sundararajan A, Saiyed S, Dhama K, Natesan S. Impact of COVID-19 on women and children and the need for a gendered approach in vaccine development. Hum Vaccines Immunother. 2020;16(12):2932–37. doi:10.1080/21645515.2020.1826249.
   PubMed Web of Science ®Google Scholar
• Sharun K, Dhama K. COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic. Arch Med Res. 2021;52(7):761–63. doi:10.1016/j.arcmed.2021.04.006.
   PubMed Web of Science ®Google Scholar
• Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Al Mutair MA. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccines Immunother. 2021;17(10):3491–94. doi:10.1080/21645515.2021.1923350.
   PubMed Web of Science ®Google Scholar
• Aschwanden C. Five reasons why COVID herd immunity is probably impossible. Nature. 2021;591:520–22. doi:10.1038/d41586-021-00728-2.
   PubMed Web of Science ®Google Scholar
• Baldo V, Reno C, Cocchio S, Fantini MP. SARS-CoV-2/COVID-19 vaccines: the promises and the challenges ahead. Vaccines. 2021;9:1–4. doi:10.3390/vaccines9010021.
   Web of Science ®Google Scholar
• Dhama K, Patel SK, Natesan S, Vora KS, Iqbal Yatoo M, Tiwari R, Saxena SK, Singh KP, Singh R, Malik YS. COVID-19 in the elderly people and advances in vaccination approaches. Hum Vaccines Immunother. 2020;16(12):2938–43. doi:10.1080/21645515.2020.1842683.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TE, Rabaan AA, Alhumaid S. COVID-19 vaccine hesitancy – reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccines Immunother. 2021;17(10):3495–99. doi:10.1080/21645515.2021.1926183.
   PubMed Web of Science ®Google Scholar
• dos Santos WG. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;136:111272. doi:10.1016/j.biopha.2021.111272.
   PubMed Web of Science ®Google Scholar
• Piret J, Boivin G, Soleimanpour S, Yaghoubi A, Poland GA, Baviskar T, Raut D, Bhatt LK, Forni G, Mantovani A, et al. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;11:8–21.
   Google Scholar
• Pennington TH. Herd immunity: Could it bring the COVID-19 pandemic to an end? Future Microbiol. 2021;16(6):371–74. doi:10.2217/fmb-2020-0293.
   PubMed Web of Science ®Google Scholar
• Redwan EM. COVID-19 pandemic and vaccination build herd immunity. Eur Rev Med Pharmacol Sci. 2021;25(2):577–79. doi:10.26355/eurrev_202101_24613.
   PubMed Web of Science ®Google Scholar
• Tiboni M, Casettari L, Illum L. Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines? Int J Pharm. 2021;603:120686. doi:10.1016/j.ijpharm.2021.120686.
   PubMedGoogle Scholar
• Park J-G, Oladunni FS, Rohaim MA, Whittingham-Dowd J, Tollitt J, Assas BM, Alhazmi W, Almilaibary A, Iqbal M, Chang P, et al. Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 in preclinical animal models. bioRxiv 2021;
   Google Scholar
• Bleier BS, Ramanathan M, Lane AP. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol - Head Neck Surg (United States). 2021;164(2):305–07. doi:10.1177/0194599820982633.
   Google Scholar
• Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccines Immunother. 2020;16(12):2921–31. doi:10.1080/21645515.2020.1805992.
   PubMed Web of Science ®Google Scholar
• Travis CR. As plain as the nose on your face: the case for a nasal (mucosal) route of vaccine administration for Covid-19 disease prevention. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.591897.
   PubMed Web of Science ®Google Scholar
• He J, Huang JR, Zhang YL, Zhang J. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice. J Med Virol. 2021;93(4):1923–25. doi:10.1002/jmv.26769.
   PubMed Web of Science ®Google Scholar
• Hoseini-Tavassol Z, Ejtahed H-S, Soroush A-R, Sajjadpour Z, Hasani-Ranjbar S, Larijani B. Natural derived nasal spray; a proposed approach for COVID-19 disease control. Infect Disord - Drug Targets. 2021;21(8):21. doi:10.2174/1871526521666210218201113.
   Google Scholar
• Kumar A, Kumar A. Mucosal and transdermal vaccine delivery strategies against COVID-19. Drug Deliv Transl Res. 2021. doi:10.1007/s13346-021-01001-9.
   Web of Science ®Google Scholar
• Bricker T, Darling T, Hassan AO, Harastani H, Soung A, Jiang X, Dai Y-N, Zhao H, Adams LJ, Holtzman MJ, et al. A single intranasal or intramuscular immunization with Chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in Hamsters. SSRN Electron J. 2021. doi:10.2139/ssrn.3773804.
   Google Scholar
• King RG, Silva-Sanchez A, Peel JN, Botta D, Dickson AM, Pinto AK, Meza-Perez S, Allie SR, Schultz MD, Liu M et al. Single-Dose intranasal administration of AdCOVID Elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects Mice from lethal challenge. Vaccines (Basel). ;9(8):881. doi:10.3390/vaccines9080881.
   PubMed Web of Science ®Google Scholar
• Du Y, Xu Y, Feng J, Hu L, Zhang Y, Zhang B, Guo W, Mai R, Chen L, Fang J, et al. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse. Vaccine. 2021;39:2280–87. doi:10.1016/j.vaccine.2021.03.006.
   PubMed Web of Science ®Google Scholar
• Ku MW, Bourgine M, Authié P, Lopez J, Nemirov K, Moncoq F, Noirat A, Vesin B, Nevo F, Blanc C, et al. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe. 2021;29(2):236–49.e6. doi:10.1016/j.chom.2020.12.010.
   PubMed Web of Science ®Google Scholar
• Sui Y, Li J, Zhang R, Prabhu SK, Andersen H, Venzon D, Cook A, Brown R, Teow E, Velasco J, et al. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight. 2021;6(10):6. doi:10.1172/jci.insight.148494.
   Web of Science ®Google Scholar
• van Doremalen N, Purushotham JN, Schulz JE, Holbrook MG, Bushmaker T, Carmody A, Port JR, Yinda CK, Okumura A, Saturday G, et al. Intranasal ChAdox1 nCov-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021;13(607):eabh0755. doi:10.1126/scitranslmed.abh0755.
   PubMed Web of Science ®Google Scholar
• Hassan AO, Shrihari S, Gorman MJ, Ying B, Yaun D, Raju S, Chen RE, Dmitriev IP, Kashentseva E, Adams LJ, et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021;36(4):109452. doi:10.1016/j.celrep.2021.109452.
   PubMed Web of Science ®Google Scholar
• CanSino Biologics Inc. A randomized, double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and immunogenicity of Ad5-nCov for inhalation in adults 18 years of age and older. 2021; clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04840992
   Google Scholar
• Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCov) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654–64. doi:10.1016/S1473-3099(21)00396-0.
   PubMed Web of Science ®Google Scholar
• Altimmune, Inc. Phase 2, double-blind, randomized, placebo-controlled study of NasoVAX in the prevention of clinical worsening in patients with early coronavirus infectious disease 2019 (COVID-19). clinicaltrials.gov. USA: Altimmune, Inc. 2020.
   Google Scholar
• Kong TU of H. A phase 1, randomized, double-blinded, placebo- controlled, dose-escalation and dose-expansion study to evaluate the safety and immunogenicity of DelNS1-NCoV-RBD LAIV for COVID-19 in Healthy Adults. The University of Hong Kong, Hong Kong. https://clinicaltrials.gov/ct2/show/NCT04809389
   Google Scholar
• Meissa Vaccines I Phase 1, open-label, dose-escalation study to evaluate tolerability, safety, and immunogenicity of an intranasal live attenuated respiratory syncytial virus vaccine expressing Spike protein of SARS-CoV-2 in healthy adults ages 18–69 Years.
   Google Scholar
• First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate. https://www.europeanpharmaceuticalreview.com/news/139089/first-patient-dosed-with-covi-vac-an-intranasal-covid-19-vaccine-candidate/
   Google Scholar
• Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov Today. 26(11): 2619–2636. doi:10.1016/j.drudis.2021.07.021.
   PubMed Web of Science ®Google Scholar
• Klouwens MJ, Salverda ML, Trentelman JJ, Ersoz JI, Wagemakers A, Gerritzen MJ, van der Ley PA, Hovius JW. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis. Vaccines. 39(18): 2561–2567. doi:10.1016/j.vaccine.2021.03.059.
   PubMedGoogle Scholar
• Gaspar EB, Prudencio CR, De Gaspari E. Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines. Hum Vaccines Immunother. 2021;17(9):2965–68. doi:10.1080/21645515.2021.1920272.
   PubMed Web of Science ®Google Scholar
• https://covid19.trackvaccines.org/vaccines/66/#trial-rpcec00000345 [Accessed on August 12, 2021].
   Google Scholar
• AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital. www.oindpnews.com/2021/01/auravax-therapeutics-licences-intranasal-vaccine-adjuvant-technology-from-massachusetts-general-Hosp
   Google Scholar
• An X, Martinez MP, Rezvan A, Sefat SR, Fathi M, Singh S, Biswas S, Pourpak M, Yee C, Liu X, et al. Single-Dose intranasal vaccination Elicits systemic and mucosal immunity against SARS-CoV-2. SSRN Electron J. 2020. doi:10.2139/ssrn.3751056.
   Google Scholar
• Seo SH, Jang Y. Cold-Adapted live attenuated sars-cov-2 vaccine completely protects human ace2 transgenic mice from sars-cov-2 infection. Vaccines. 2020;8:1–17. doi:10.3390/vaccines8040584.
   Web of Science ®Google Scholar
• Acharya R. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate. Med Hypotheses. 2020;143:143. doi:10.1016/j.mehy.2020.110084.
   Web of Science ®Google Scholar
• Chakraborty C, Agoramoorthy G. India’s cost-effective COVID-19 vaccine development initiatives. Vaccine. 2020;38:7883–84. doi:10.1016/j.vaccine.2020.10.056.
   PubMed Web of Science ®Google Scholar
• Codagenix Inc. Codagenix and Serum Institute of India initiate dosing in phase 1 trial of COVI-VAC, a single dose, intranasal, live attenuated vaccine for COVID-19. 2021;. https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-dosing-in-phase-1-trial-of-covi-vac-a-single-dose-intranasal-live-attenuated-vaccine-for-covid-19-301203130.html
   Google Scholar
• Sharun K, Dhama K. India’s role in COVID-19 vaccine diplomacy. J Travel Med. 2021;28(7). doi:10.1093/jtm/taab064.
   PubMed Web of Science ®Google Scholar
• Bharat Biotech’s nasal vaccine can be a gamechanger in fight against Covid: all you need to know.
   Google Scholar
• van Doremalen N, Purushotham J, Schulz J, Holbrook M, Bushmaker T, Carmody A, Port J, Yinda KC, Okumura A, Saturday G, et al. Intranasal ChAdox1 nCov-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. bioRxiv Prepr Serv Biol; 2021. https://pubmed.ncbi.nlm.nih.gov/33447831/
   Google Scholar
• Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, Chen RE, Winkler ES, Wessel AW, Case JB, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169–84.e13. doi:10.1016/j.cell.2020.08.026.
   PubMed Web of Science ®Google Scholar
• Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huau TL, Case JB, Meade-White K, Callison J, Chen RE, et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Reports Med. 2021;2(4):100230. doi:10.1016/j.xcrm.2021.100230.
   PubMedGoogle Scholar
• Kim E, Weisel FJ, Balmert SC, Khan MS, Huang S, Erdos G, Kenniston TW, Carey CD, Joachim SM, Conter LJ, et al. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. Eur J Immunol. 2021;51(7):1774–84. doi:10.1002/eji.202149167.
   PubMed Web of Science ®Google Scholar
• Bakkari MA, Valiveti CK, Kaushik RS, Tummala H. Toll-Like receptor-4 (TLR4) agonist-based intranasal nanovaccine delivery system for inducing systemic and mucosal immunity. Mol Pharm. 2021;18(6):2233–41. doi:10.1021/acs.molpharmaceut.0c01256.
   PubMedGoogle Scholar
• Jearanaiwitayakul T, Seesen M, Chawengkirttikul R, Limthongkul J, Apichirapokey S, Sapsutthipas S, Phumiamorn S, Sunintaboon P, Ubol S. Intranasal administration of RBD nanoparticles confers induction of mucosal and systemic immunity against SARS-CoV-2. Vaccines. 2021;9:768. doi:10.3390/vaccines9070768.
   PubMed Web of Science ®Google Scholar
• Chandrasekar SS, Phanse Y, Hildebrand RE, Hanafy M, Wu CW, Hansen CH, Osorio JE, Suresh M, Talaat AM. Localized and systemic immune responses against sars-cov-2 following mucosal immunization. Vaccines. 2021;9(2):1–17. doi:10.3390/vaccines9020132.
   Web of Science ®Google Scholar
• Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619–36. doi:10.1016/j.drudis.2021.07.021.
   PubMed Web of Science ®Google Scholar
• Nainu F, Abidin RS, Bahar MA, Frediansyah A, Emran TB, Rabaan AA, Dhama K, Harapan H. SARS-CoV-2 reinfection and implications for vaccine development. Hum Vaccines Immunother. 2020;16(12):3061–73. doi:10.1080/21645515.2020.1830683.
   PubMed Web of Science ®Google Scholar
• A H. Antibody responses to natural SARS-CoV-2 Infection or after COVID-19 vaccination. Vaccines. 2021;9:910. doi:10.3390/vaccines9080910.
   Web of Science ®Google Scholar
• Fröberg J, Diavatopoulos DA. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Infect Dis. 2021;34(3):181–86. doi:10.1097/QCO.0000000000000724.
   PubMed Web of Science ®Google Scholar
• Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, et al. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. bioRxiv Prepr Serv Biol; 2021. http://www.ncbi.nlm.nih.gov/pubmed/33501447%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7836117
   Google Scholar
• Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021;14(2):305–16. doi:10.1038/s41385-020-00359-2.
   PubMed Web of Science ®Google Scholar
• Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):6. doi:10.1038/s41541-021-00292-w.
   PubMed Web of Science ®Google Scholar
• Park JH, Lee HK. Delivery routes for COVID-19 vaccines. Vaccines. 2021;9:524. doi:10.3390/vaccines9050524.
   PubMed Web of Science ®Google Scholar
• Choudhary OP, Mohammed TA, Singh I, Singh I. Intranasal COVID-19 vaccines: is it a boon or bane? Int J Surg. 2021;94:106119. doi:10.1016/j.ijsu.2021.106119.
   PubMed Web of Science ®Google Scholar
• Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Intranasal COVID-19 vaccines: from bench to bed. eBiomedicine. 2022;76. doi:10.1016/j.ebiom.2022.103841.
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal Influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004;350(9):896–903. doi:10.1056/NEJMoa030595.
   PubMed Web of Science ®Google Scholar
• Lemiale F, Kong W, Akyürek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ. Enhanced mucosal immunoglobulin a response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol. 2003;77(18):10078–87. doi:10.1128/JVI.77.18.10078-10087.2003.
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2):148–58. doi:10.1038/nri1777.
   PubMed Web of Science ®Google Scholar
• Bernasconi V, Norling K, Bally M, Höök F, Lycke NY. Mucosal vaccine development based on Liposome technology. J Immunol Res. 2016;2016:1–16. doi:10.1155/2016/5482087.
   Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi:10.1016/j.smim.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Arunachalam SP, O’-Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–75. doi:10.1038/s41573-021-00163-y.
   PubMed Web of Science ®Google Scholar
• Wang X, Meng D. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell. 2015;6(3):170–84. doi:10.1007/s13238-014-0125-1.
   PubMed Web of Science ®Google Scholar
• Aoshi T. Modes of action for mucosal vaccine adjuvants. Viral Immunol. 2017;30(6):463–70. doi:10.1089/vim.2017.0026.
   PubMed Web of Science ®Google Scholar
• Jin Z, Gao S, Cui X, Sun D, Zhao K. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines. Int J Pharm. 2019;572:572. doi:10.1016/j.ijpharm.2019.118731.
   Google Scholar
• O’-Hagan DT, Lodaya RN, Lofano G. The continued advance of vaccine adjuvants - 'we can work it out'. Semin Immunol. 2020;50:50. doi:10.1016/j.smim.2020.101426.
   Web of Science ®Google Scholar
• Mallakpour S, Azadi E, Hussain M. Chitosan, alginate, hyaluronic acid, gums, and β-glucan as potent adjuvants and vaccine delivery systems for viral threats including SARS-CoV-2: A review. Int J Biol Macromol. 2021;182:1931–40. doi:10.1016/j.ijbiomac.2021.05.155.
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into Olfactory tissues. J Immunol. 2000;165(9):4778–82. doi:10.4049/jimmunol.165.9.4778.
   PubMed Web of Science ®Google Scholar
• Vasu N, Ghaffari G, Craig ET, Craig TJ. Adverse events associated with intranasal influenza vaccine in the United States. Ther Adv Respir Dis. 2008;2(4):193–98. doi:10.1177/1753465808093933.
   PubMedGoogle Scholar
• Sarkar I, Garg R, van Drunen Littel-van den Hurk S. Selection of adjuvants for vaccines targeting specific pathogens. Expert Rev Vaccines. 2019;18(5):505–21. doi:10.1080/14760584.2019.1604231.
   PubMed Web of Science ®Google Scholar
• Islam F, Bibi S, Meem AF, Islam M, Rahaman M, Bepary S, Rahman M, Elzaki A, Kajoak S, Osman H, et al. Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. Int J Mol Sci. 22(23):2021;12638. doi:10.3390/ijms222312638.
   PubMed Web of Science ®Google Scholar
• Sharma R, Palanisamy A, Dhama K, Mal G, Singh B, Singh KP. Exploring the possible use of saponin adjuvants in COVID-19 vaccine. Hum Vaccines Immunother. 2020;16(12):2944–53. doi:10.1080/21645515.2020.1833579.
   PubMed Web of Science ®Google Scholar
• Abbasi S, Uchida S. Multifunctional immunoadjuvants for use in minimalist nucleic acid vaccines. Pharmaceutics. 2021;13(5):13. doi:10.3390/pharmaceutics13050644.
   Web of Science ®Google Scholar
• Bouazzaoui A, Abdellatif AAH, Al-Allaf FA, Bogari NM, Al-Dehlawi S, Qari SH. Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants. Pharmaceutics. 2021;13:1–20. doi:10.3390/pharmaceutics13020140.
   Web of Science ®Google Scholar
• Mao L, Chen Z, Wang Y, Chen C. Design and application of nanoparticles as vaccine adjuvants against human corona virus infection. J Inorg Biochem. 2021;219:219. doi:10.1016/j.jinorgbio.2021.111454.
   Web of Science ®Google Scholar
• Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11(9):1200–03. doi:10.1021/acschemneuro.0c00172.
   PubMed Web of Science ®Google Scholar
• Ma XC, Liu P, Zhang XL, Jiang WH, Jia M, Wang CX, Dong YY, Dang YH, Gao CG. Intranasal delivery of recombinant AAV containing BDNF fused with HA2TAT: a potential promising therapy strategy for major depressive disorder. Sci Rep. 2016;6:6. doi:10.1038/srep22404.
   PubMed Web of Science ®Google Scholar
• Illum L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci. 2007;96(3):473–83. doi:10.1002/jps.20718.
   PubMed Web of Science ®Google Scholar
• Francisco ARL, Sherman W, Repasky M, Beuming T. Improved docking of polypeptides with glide. J Chem Inf Model. 2013;53(7):1689–99. doi:10.1021/ci400128m.
   PubMed Web of Science ®Google Scholar